Epigallocatechin 3-gallate attenuates arthritis by regulating Nrf2, HO-1, and cytokine levels in an experimental arthritis model

dc.contributor.authorKaratas, Ahmet
dc.contributor.authorDagli, Adile Ferda
dc.contributor.authorOrhan, Cemal
dc.contributor.authorGencoglu, Hasan
dc.contributor.authorOzgen, Metin
dc.contributor.authorSahin, Nurhan
dc.contributor.authorKoca, Suleyman Serdar
dc.date.accessioned2026-08-12T17:18:17Z
dc.date.issued2020
dc.departmentFırat Üniversitesi
dc.description.abstractEpigallocatechin 3-gallate (EGCG) is a polyphenol that has been shown to have antioxidant and anti-inflammatory effects. In this study, collagen-induced arthritis (CIA) model, in Wistar albino rats, was used to elucidate the effect of EGCG on pathogenetic pathways in inflammatory arthritis. The levels of serum TNF-alpha, IL-17, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx); the expression levels of tissue heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2); histopathologically, perisynovial inflammation and cartilage-bone destruction were examined. In the sham group, serum TNF-alpha, IL-17, and MDA levels increased, while SOD, CAT, GPx levels, and the expressions of Nrf2 and HO-1 decreased. On the other hand, in the EGCG administered groups, serum TNF-alpha, IL-17, and MDA levels improved, while SOD, CAT, GPx levels and the expressions of Nrf2 and HO-1 increased. Moreover, histopathological analysis has shown that perisynovial inflammation and cartilage-bone destruction decreased in the EGCG administered groups. These results suggest that EGCG has an antiarthritic effect by regulating the oxidative-antioxidant balance and cytokine levels in the CIA model, which is a surrogate experimental model of rheumatoid arthritis.
dc.identifier.doi10.1002/bab.1860
dc.identifier.endpage322
dc.identifier.issn0885-4513
dc.identifier.issn1470-8744
dc.identifier.issue3
dc.identifier.orcid0000-0001-9542-5244
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.orcid0000-0002-7716-552X
dc.identifier.orcid0000-0003-4138-7689
dc.identifier.orcid0000-0002-6725-4182
dc.identifier.pmid31746064
dc.identifier.scopus2-s2.0-85076164431
dc.identifier.scopusqualityQ1
dc.identifier.startpage317
dc.identifier.urihttps://doi.org/10.1002/bab.1860
dc.identifier.urihttps://hdl.handle.net/11508/52980
dc.identifier.volume67
dc.identifier.wosWOS:000555601200002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofBiotechnology and Applied Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectcollagen-induced arthritis
dc.subjectepigallocatechin 3-gallate
dc.subjectrheumatoid arthritis
dc.titleEpigallocatechin 3-gallate attenuates arthritis by regulating Nrf2, HO-1, and cytokine levels in an experimental arthritis model
dc.typeArticle

Dosyalar